Consensus report: definition and interpretation of remission in type 2 diabetes.
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
17
06
2021
accepted:
17
06
2021
pubmed:
31
8
2021
medline:
26
3
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment. However, terminology for describing this process and objective measures for defining it are not well established, and the long-term risks vs benefits of its attainment are not well understood. To update prior discussions of this issue, an international expert group was convened by the American Diabetes Association to propose nomenclature and principles for data collection and analysis, with the goal of establishing a base of information to support future clinical guidance. This group proposed 'remission' as the most appropriate descriptive term, and HbA
Identifiants
pubmed: 34458934
doi: 10.1007/s00125-021-05542-z
pii: 10.1007/s00125-021-05542-z
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
hemoglobin A1c protein, human
0
Types de publication
Consensus Development Conference
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2359-2366Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. Endocrine Society, European Association for the Study of Diabetes, Diabetes UK, and American Diabetes Association.
Références
Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL (2020) Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 369:m1361. https://doi.org/10.1136/bmj.m1361
doi: 10.1136/bmj.m1361
pubmed: 32404325
pmcid: 7218708
Simmons LR, Molyneaux L, Yue DK, Chua EL (2012) Steroid-induced diabetes: is it just unmasking of type 2 diabetes? ISRN Endocrinol 2012:910905. https://doi.org/10.5402/2012/910905
doi: 10.5402/2012/910905
pubmed: 22830041
pmcid: 3398625
Li Z, Cheng Y, Wang D et al (2020) Incidence rate of type diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women. J Diab Res 3076463. https://doi.org/10.16250/j.32.1374.2019179
Selvin E, Ning Y, Steffes MW et al (2011) Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 60:298–305
doi: 10.2337/db10-1198
Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489. https://doi.org/10.1016/S0140-6736(09)61969-3
doi: 10.1016/S0140-6736(09)61969-3
pubmed: 20110121
Carson AP, Fox CS, McGuire DK et al (2010) Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 3:661–667. https://doi.org/10.1161/CIRCOUTCOMES.110.957936
doi: 10.1161/CIRCOUTCOMES.110.957936
pubmed: 20923991
pmcid: 4734630
Kramer CK, Zinman B, Retnakaran R (2013) Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 1:28–34. https://doi.org/10.1016/S2213-8587(13)70006-8
doi: 10.1016/S2213-8587(13)70006-8
pubmed: 24622264
Kramer CK, Zinman B, Choi H, Retnakaran R (2016) Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Res Care 4:e000270. https://doi.org/10.1136/bmjdrc-2016-000270
doi: 10.1136/bmjdrc-2016-000270
pubmed: 27547422
pmcid: 4985916
McInnes N, Smith A, Otto R et al (2017) Piloting a remission strategy in type 2 diabetes: results of a randomized controlled trial. J Clin Endocrinol Metab 102:1596–1605. https://doi.org/10.1210/jc.2016-3373
doi: 10.1210/jc.2016-3373
pubmed: 28324049
Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 7:344–355. https://doi.org/10.1016/S2213-8587(19)30068-3
doi: 10.1016/S2213-8587(19)30068-3
pubmed: 30852132
Gregg EW, Chen H, Wagenknecht LE et al (2012) Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 308:2489–2496. https://doi.org/10.1001/jama.2012.67929
doi: 10.1001/jama.2012.67929
pubmed: 23288372
pmcid: 4771522
Mingrone G, Panunzi S, De Gaetano A et al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 397:293–304. https://doi.org/10.1016/S0140-6736(20)32649-0
doi: 10.1016/S0140-6736(20)32649-0
pubmed: 33485454
Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39:861–877. https://doi.org/10.2337/dc16-0236
doi: 10.2337/dc16-0236
Schauer PR, Bhatt DL, Kirwan JP et al (2017) STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med 376:641–651. https://doi.org/10.1056/NEJMoa1600869
doi: 10.1056/NEJMoa1600869
pubmed: 5451258
pmcid: 5451258
White MG, Shaw JAM, Taylor R (2016) Type 2 diabetes: the pathologic basis of reversible β-cell dysfunction. Diabetes Care 39:2080–2088. https://doi.org/10.2337/dc16-0619
doi: 10.2337/dc16-0619
pubmed: 27926891
Buse JB, Caprio S, Cefalu WT et al (2009) How do we define cure of diabetes? Diabetes Care 32:2133–2135. https://doi.org/10.2337/dc09-9036
doi: 10.2337/dc09-9036
pubmed: 19875608
pmcid: 2768219
Nagi D, Hambling C, Taylor R (2019) Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS). Br J Diabetes 19:73–76. https://doi.org/10.15277/bjd.2019.221
doi: 10.15277/bjd.2019.221
Barnes E (2007) Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century. Chronic Illn 3:253–264. https://doi.org/10.1177/1742395307085333
doi: 10.1177/1742395307085333
pubmed: 18083680
Taylor R, Al-Mrabeh A, Zhyzhneuskaya S et al (2018) Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab 28:547–556.e3. https://doi.org/10.1016/j.cmet.2018.07.003
doi: 10.1016/j.cmet.2018.07.003
pubmed: 30078554
Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R (2011) Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54:2506–2514. https://doi.org/10.1007/s00125-011-2204-7
doi: 10.1007/s00125-011-2204-7
pubmed: 21656330
pmcid: 3168743
Camastra S, Manco M, Mari A et al (2007) Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. Diabetes Care 30:1002–1004. https://doi.org/10.2337/dc06-1845
doi: 10.2337/dc06-1845
pubmed: 17392562
The American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation (2007) Consensus statement on the worldwide standardisation of the HbA
doi: 10.1007/s00125-007-0789-7
Jeppsson J-O, Kobold U, Barr J et al (2002) International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 40:78–89. https://doi.org/10.1515/CCLM.2002.016
doi: 10.1515/CCLM.2002.016
pubmed: 11916276
EurA1c Trial Group (2018) EurA1c: the European HbA1c trial to investigate the performance of HbA1c assays in 2166 laboratories across 17 countries and 24 manufacturers by use of the IFCC model for quality targets. Clin Chem 64:1183–1192. https://doi.org/10.1373/clinchem.2018.288795
doi: 10.1373/clinchem.2018.288795
Danne T, Nimri R, Battelino T et al (2017) International consensus on use of continuous glucose monitoring. Diabetes Care 40:1631–1640. https://doi.org/10.2337/dc17-1600
doi: 10.2337/dc17-1600
pubmed: 29162583
pmcid: 6467165
Bergenstal RM, Beck RW, Close KL et al (2018) Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care 41:2275–2280. https://doi.org/10.2337/dc18-1581
doi: 10.2337/dc18-1581
pubmed: 30224348
pmcid: 6196826
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM (2017) The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 40:994–999. https://doi.org/10.2337/dc17-0636
doi: 10.2337/dc17-0636
pubmed: 28733374
pmcid: 5521971
Shah VN, DuBose SN, Li Z et al (2019) Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study. J Clin Endocrinol Metab 104:4356–4364. https://doi.org/10.1210/jc.2018-02763
doi: 10.1210/jc.2018-02763
pubmed: 31127824
pmcid: 7296129
Hundal RS, Inzucchi SE (2003) Metformin: new understandings, new uses. Drugs 63:1879–1894. https://doi.org/10.2165/00003495-200363180-00001
doi: 10.2165/00003495-200363180-00001
pubmed: 12930161
Herman WH, Ratner RE (2020) Metformin should be used to treat prediabetes in selected individuals. Diabetes Care 43:1988–1990. https://doi.org/10.2337/dci20-0030
doi: 10.2337/dci20-0030
pubmed: 32964858
Davidson MB (2020) Metformin should not be used to treat prediabetes. Diabetes Care 43:1983–1987. https://doi.org/10.2337/dc19-2221
doi: 10.2337/dc19-2221
pubmed: 32936780
Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13:415–431. https://doi.org/10.1210/edrv-13-3-415
doi: 10.1210/edrv-13-3-415
pubmed: 1425483
Isaman DJ, Rothberg AE, Herman WH (2016) Reconciliation of type 2 diabetes remission rates in studies of Roux-en-Y gastric bypass. Diabetes Care 39:2247–2253. https://doi.org/10.2337/dc16-0954
doi: 10.2337/dc16-0954
pubmed: 27737910
pmcid: 5127233
Ceriello A (2012) The emerging challenge in diabetes: the “metabolic memory.”. Vasc Pharmacol 57:133–138. https://doi.org/10.1016/j.vph.2012.05.005
doi: 10.1016/j.vph.2012.05.005
Murphy R, Jiang Y, Booth M et al (2015) Progression of diabetic retinopathy after bariatric surgery. Diabet Med 32:1212–1220. https://doi.org/10.1111/dme.12727
doi: 10.1111/dme.12727
pubmed: 25689226
Arun CS, Pandit R, Taylor R (2004) Long-term progression of retinopathy after initiation of insulin therapy in type 2 diabetes: an observational study. Diabetologia 47:1380–1384. https://doi.org/10.1007/s00125-004-1473-9
doi: 10.1007/s00125-004-1473-9
pubmed: 15309288
The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874–886. https://doi.org/10.1001/archopht.116.7.874
doi: 10.1001/archopht.116.7.874
Singh RP, Gans R, Kashyap SR et al (2015) Effect of bariatric surgery versus intensive medical management on diabetic ophthalmic outcomes. Diabetes Care 38:e32–e33. https://doi.org/10.2337/dc14-2035
doi: 10.2337/dc14-2035
pubmed: 25715418
pmcid: 4338505